Search results
FibroGen Stock Is Surging After The Bell: What's Going On? - FibroGen (NASDAQ:FGEN)
Benzinga· 2 days agoThe company also announced a new clinical trial supply agreement with Regeneron. What Happened:...
The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks
Investor's Business Daily· 5 days agoIn another study, the pain drug proved it wasn't inferior to opioids in patients after a tummy tuck....
FDA Extends Review Deadline For Regeneron/Sanofi's Dupixent For 'Smoker's Lungs' Disease
Benzinga via Yahoo Finance· 5 days agoOn Friday, the FDA extended the target action date of priority review of supplemental application...
Is Intellia Therapeutics, Inc. (NASDAQ:NTLA) the Most Promising Gene Therapy Stock to Buy Now?
Insider Monkey via Yahoo Finance· 2 days agoWe recently compiled a list of the 9 Best Gene Therapy Stocks to Buy Now and in this article, we...
Cracking The Code: Understanding Analyst Reviews For Intellia Therapeutics - Intellia Therapeutics...
Benzinga· 23 hours agoHow Are Analyst Ratings Determined? Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists ...
CAC 40 Struggles For Direction As Inflation Accelerates
RTT News· 5 days agoFrench stocks struggled for direction on Friday after data showed consumer prices in the country rose at a faster rate this month due to higher energy prices. Consumer prices rose an average ...
Intellia (NTLA) Up on Upbeat Long-Term Angioedema Study Data
Zacks· 2 days agoIntellia (NTLA) gains 10% after reporting encouraging long-term efficacy data from the phase I portion of its early to mid-stage study evaluating NTLA-2002 for treating hereditary angioedema.
Morning Brew: Broadcom and Marvell to Dominate Custom Chip Marke
Guru Focus· 1 day agoS&P futures vs fair value: -18.00. Nasdaq futures vs fair value: -52.00.The S&P 500 futures are down...
Intellia Up on Upbeat Long-Term Angioedema Study Data - Annovis Bio (NYSE:ANVS), ALX Oncology...
Benzinga· 24 hours agoIntellia Therapeutics' NTLA shares gained 10% on Jun 3 after the company reported encouraging...